EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

An in silico framework for the rational design of vaginal probiotic therapy

Christina Y Lee, Sina Bonakdar, Kelly B Arnold iD

PLOS Computational Biology · 2025

DOI: 10.1371/journal.pcbi.1012064 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Computational Biology, 2025. Verfasst von Christina Y Lee und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan, United States of America. Hauptthemen laut MEDLINE: Probiotics, Vaginosis, Bacterial, Vagina, Models, Biological. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bacterial vaginosis ( BV ) is a common condition characterized by a shift in vaginal microbiome composition that is linked to negative reproductive outcomes and increased susceptibility to sexually transmitted infections. Despite the commonality of BV, standard-of-care antibiotics provide limited control of recurrent BV episodes and development of new biotherapies is limited by the lack of controlled models needed to evaluate new dosing and treatment regimens. Here, we develop an in silico framework to evaluate selection criteria for potential probiotic strains, test adjunctive therapy with antibiotics, and alternative dosing strategies. This computational framework highlighted the importance of resident microbial species on the efficacy of hypothetical probiotic strains, identifying specific interaction parameters between resident non-optimal anaerobic bacteria (nAB) and Lactobacillus spp. with candidate probiotic strains as a necessary selection criterion. Model predictions were able to replicate results from a recent phase 2b clinical trial for the live biotherapeutic product, Lactin-V, demonstrating the relevance of the in silico platform. Results from the computational model support that the probiotic strain in Lactin-V requires adjunctive antibiotic therapy to be effective, and that increasing the dosing frequency of the probiotic could have a moderate impact on BV recurrence at 12 and 24 weeks. Altogether, this framework could provide evidence for the rational selection of probiotic strains and help optimize dosing frequency or adjunctive therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProbioticsVaginosis, BacterialVaginaModels, BiologicalFemaleHumansComputer SimulationAnti-Bacterial AgentsComputational BiologyAdministration, IntravaginalLactobacillus

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan, United States of America.

ORCID-Profile: Kelly B Arnold

Förderung

  • NIGMS NIH HHS
  • National Institute of General Medical Sciences

Zitieren

APA

Lee, C. Y., Bonakdar, S., & Arnold, K. B. (2025). An in silico framework for the rational design of vaginal probiotic therapy. PLOS Computational Biology. https://doi.org/10.1371/journal.pcbi.1012064

Vancouver

Lee CY, Bonakdar S, Arnold KB. An in silico framework for the rational design of vaginal probiotic therapy. PLOS Computational Biology. 2025. doi:10.1371/journal.pcbi.1012064

BibTeX
@article{Lee2025,
  author = {Lee, Christina Y and Bonakdar, Sina and Arnold, Kelly B},
  title = {An in silico framework for the rational design of vaginal probiotic therapy},
  journal = {PLOS Computational Biology},
  year = {2025},
  doi = {10.1371/journal.pcbi.1012064}
}
Kostenlos starten →